EGFR and non-small cell lung carcinoma: An example of the power of targeted therapies in a precision medicine approach was demonstrated in 2004 by Lynch et al. (12) and Paez et al. (13) who demonstrated that patients with EGFR mutations present in the tumors of patients with non-small cell lung cancer exhibited a dramatic response to getfitinib, the epidermal growth factor (EGFR) tyrosine kinase inhibitor (TKI), bringing personalized medicine to reality for a subset of NSCLC patients (12, 13).